postinfecti
immun
respiratori
syncyti
viru
rsv
infect
result
limit
protect
evidenc
high
rate
infant
hospit
face
high
titer
matern
deriv
rsvspecif
antibodi
contrast
rsv
fusion
f
glycoprotein
antigen
site
ii
human
monoclon
antibodi
palivizumab
motavizumab
shown
reduc
rsvrelat
hospit
infant
immunogen
efficaci
studi
conduct
cotton
rat
compar
recombin
rsv
f
nanoparticl
vaccin
palivizumab
control
live
rsv
viru
intranas
immun
formalin
inactiv
rsv
vaccin
activ
immun
rsv
f
nanoparticl
vaccin
contain
alum
adjuv
induc
serum
level
palivizumab
compet
antibodi
pca
greater
passiv
administr
mgkg
palivizumab
human
prophylact
dose
cotton
rat
neutral
rsva
rsvb
virus
immun
prevent
detect
rsv
replic
lung
unlik
passiv
administr
palivizumab
nasal
passag
challeng
cotton
rat
histolog
lung
tissu
follow
rsv
challeng
show
enhanc
diseas
vaccin
group
contrast
formalin
inactiv
lot
vaccin
passiv
intramuscular
administr
rsv
f
vaccineinduc
immun
sera
one
day
prior
challeng
cotton
rat
reduc
viral
titer
log
viru
per
gram
lung
nasal
tissu
dose
less
palivizumab
recombin
rsv
f
nanoparticl
vaccin
protect
lower
upper
respiratori
tract
rsv
b
strain
infect
induc
polyclon
palivizumab
compet
antibodi
similar
potenti
broadli
protect
rsv
palivizumab
respiratori
syncyti
viru
rsv
lead
caus
sever
lower
respiratori
tract
diseas
infant
young
children
worldwid
import
pathogen
elderli
high
risk
adult
world
health
organ
estim
global
annual
burden
infect
mortal
due
human
rsv
million
respect
industri
countri
nearli
children
infect
rsv
year
age
infect
children
present
mild
upper
respiratori
tract
symptom
subset
develop
sever
lower
respiratori
tract
diseas
character
tachypnea
hyperinfl
crackl
expiratori
wheez
ie
bronchiol
pneumonia
sever
diseas
occur
within
first
month
life
larg
full
term
healthi
infant
data
unit
state
us
australia
suggest
infant
hospit
rsv
infect
one
year
age
us
approxim
infant
less
year
age
children
less
year
age
hospit
due
rsv
diseas
annual
rsv
import
pathogen
children
daycar
account
substanti
portion
singlepathogen
acut
respiratori
tract
infect
well
coinfect
rhinovirus
coronavirus
adenovirus
clinic
manifest
morbid
rsv
similar
among
infant
young
children
worldwid
mortal
much
higher
lesser
develop
countri
due
avail
medic
care
despit
decad
research
licens
rsv
vaccin
howev
two
monoclon
antibodi
palivizumab
synagi
motavizumab
bind
fusion
protein
viru
shown
prevent
sever
diseas
prematur
term
infant
passiv
immunoprophylaxi
efficaci
associ
inhibit
viral
infect
via
bind
amino
acid
sequenc
known
antigen
site
ii
rsv
f
protein
provid
rational
f
base
rsv
vaccin
contain
site
recent
clinic
trial
indic
year
natur
infect
thu
exposur
live
viru
induc
littl
f
specif
site
ii
antibodi
two
major
rsv
strain
cocircul
human
rsva
b
strain
two
surfac
glycoprotein
f
g
engag
host
cell
establish
propag
infect
respect
human
rsv
viral
attach
g
glycoprotein
genet
divers
compar
highli
conserv
ffusion
glycoprotein
natur
infect
frequent
age
group
result
signific
immun
respons
f
g
glycoprotein
highest
level
neutral
antibodi
appear
confer
solid
protect
reinfect
rsv
f
nanoparticl
vaccin
recombin
nearful
length
f
glycoprotein
produc
spodoptera
frugiperda
insect
cell
recombin
baculoviru
purifi
recombin
rsv
f
oligom
hatpinshap
rod
consist
postfusionlik
conform
rsv
f
cotton
rat
immun
vaccin
demonstr
protect
rsv
replic
current
studi
product
vaccineinduc
palivizumab
compet
antibodi
pca
bind
site
ii
studi
cotton
rat
assess
rel
potenc
activ
passiv
immun
studi
also
control
rsv
infect
shown
induc
limit
pca
human
final
lot
formalin
inactiv
rsv
vaccin
use
associ
diseas
enhanc
children
allow
comparison
rel
safeti
induct
function
immun
briefli
rsv
f
protein
nanoparticl
vaccin
manufactur
infect
cell
exponenti
growth
baculoviru
contain
rsv
f
gene
previous
describ
infect
cell
collect
centrifug
wash
steril
pb
lyse
presenc
releas
membran
bound
rsv
f
protein
supernat
contain
rsv
f
protein
clarifi
use
depth
filtrat
purifi
ion
exchang
trimethylaminoethyl
tmae
chromatographi
flowthrough
fraction
affin
purifi
use
lentil
lectin
wash
elut
column
buffer
contain
mmp
polysorb
ps
elut
fraction
purifi
cation
exchang
sulfat
chromatographi
product
steril
filter
formul
buffer
contain
mm
sodium
phosphat
ph
histidin
vaccin
adsorb
aluminum
phosphat
aluminum
phosphat
salt
nacl
without
buffer
purchas
brenntag
biosector
frederikssund
denmark
inbr
week
sigmodon
hispidu
cotton
rat
obtain
sigmovir
biosystem
inc
rockvil
md
studi
conduct
accord
nrc
guid
care
use
laboratori
anim
anim
welfar
act
cdcnih
biosafeti
microbiolog
medic
laboratori
applic
law
guidelin
approv
institut
anim
care
use
committe
iacuc
lot
formalininactiv
rsv
vaccin
firsv
manufactur
pfizer
rsva
long
rsvb
provid
sigmovir
inc
rsva
virus
propag
cell
pool
viru
design
hrsva
long
lot
approxim
plaqu
form
unit
pfu
ml
store
c
rsvb
rsvb
atcc
manassa
va
propag
cell
pool
viru
design
hrsvb
lot
approxim
pfuml
store
c
cotton
rat
n
immun
intramuscularli
im
day
firsv
rsvf
nanoparticl
vaccin
without
adjuv
rsv
pfu
intranas
compar
palivizumab
mgkg
given
im
one
day
prior
challeng
sera
obtain
day
day
postchalleng
rsv
challeng
perform
day
intranas
pfu
l
lnare
rsva
long
strain
lung
tissu
collect
day
dosedescal
activ
immun
studi
cotton
rat
receiv
two
vaccin
g
rsv
f
vaccin
adjuv
aluminum
phosphat
day
day
compar
palivizumab
mgkg
im
day
sera
obtain
day
prior
challeng
day
postchalleng
store
c
test
pool
immun
sera
rsv
f
nanoparticl
vaccineimmun
cotton
rat
prepar
assay
pca
elisa
describ
cotton
rat
n
passiv
immun
im
mgkg
palivizumablik
antibodi
activ
compar
palivizumab
given
mgkg
im
day
rsv
challeng
perform
day
intranas
administr
l
lnare
live
rsvb
pfu
cotton
rat
bled
day
day
follow
one
two
immun
day
day
challeng
nasal
wash
bal
nose
lung
tissu
collect
day
rsv
f
elisa
palivizumab
competit
antibodi
pca
elisa
neutral
assay
rsv
fspecif
antibodi
cotton
rat
sera
measur
enzym
link
immunosorb
assay
elisa
previous
describ
competit
inhibit
cotton
rat
sera
bind
palivizumab
monoclon
antibodi
asd
specialti
heath
care
inc
chicago
il
measur
elisa
method
previous
describ
serum
rsv
viru
neutral
titer
determin
describ
previous
five
day
intranas
rsv
challeng
cotton
rat
sacrif
lung
harvest
lung
tissu
homogen
clarifi
centrifug
g
min
viru
titer
supernat
determin
plaqu
assay
describ
previous
lung
tissu
slide
stain
hematoxylin
eosin
h
e
observ
nikon
eclips
microscop
slide
evalu
blind
fashion
use
score
none
minim
mild
moder
maximum
inflamm
order
increas
sever
follow
paramet
peribronchiol
b
perivascul
c
bronchoiol
alveol
e
interstiti
pneumon
describ
princ
et
al
summari
score
anim
group
use
gener
overal
scoregroup
express
arithmet
mean
sem
individu
anim
comparison
mean
score
group
nonimmun
anim
challeng
score
analyz
use
student
ttest
sum
score
five
paramet
per
anim
use
analysi
histopatholog
data
pair
wise
ttest
analyz
excel
gmt
ci
calcul
use
graph
pad
prizm
immun
respons
rsv
f
nanoparticl
vaccin
g
administ
im
presenc
absenc
adjuv
compar
anim
receiv
passiv
transfer
palivizumab
recommend
human
dose
mgkg
control
anim
infect
pfu
rsva
long
allow
recov
vaccin
firsv
lot
dilut
treat
placebo
three
week
second
vaccin
dose
immun
unadjuv
rsv
f
nanoparticl
vaccin
induc
titer
antirsv
f
serum
igg
fig
significantli
higher
p
ttest
cotton
rat
immun
firsv
antigen
infect
rsva
viru
p
ttest
adjuv
enhanc
rsv
f
vaccin
antibodi
titer
boost
fig
cotton
rat
receiv
palivizumab
im
inject
exhibit
lower
antirsv
f
igg
serum
titer
compar
polyclon
respons
obtain
follow
immun
adjuv
rsv
f
gmt
vs
eu
respect
fig
antigen
site
ii
rsv
f
polypeptid
target
palivizumab
palivizumab
competit
elisa
perform
quantifi
rel
level
pca
antibodi
induc
vaccin
anim
sera
immun
g
adjuv
rsv
f
nanoparticl
elicit
significantli
higher
serum
level
pca
gml
anim
receiv
mgkg
human
dose
palivizumab
gml
pca
lod
assay
gml
cotton
rat
immun
firsv
control
group
slightli
lod
rsv
intranas
immun
group
fig
sera
group
except
firsv
placebo
recipi
viru
neutral
antibodi
fig
adjuv
rsv
f
elicit
higher
neutral
titer
gmt
natur
infect
gmt
palivizumab
passiv
immun
cotton
rat
gmt
fig
neutral
titer
differ
observ
cotton
rat
receiv
adjuv
rsv
f
viru
infect
cotton
rat
statist
signific
p
follow
trend
observ
analysi
pca
antirsv
f
elisa
respons
vivo
efficaci
rsv
f
nanoparticl
vaccin
evalu
measur
inhibit
viral
replic
lung
nasal
passag
immun
cotton
rat
challeng
rsv
complet
inhibit
viru
replic
observ
lung
cotton
rat
immun
live
rsv
rsv
f
nanoparticl
administ
without
adjuv
well
palivizumab
given
passiv
fig
firsv
reduc
lung
viral
load
pfug
tissu
immun
respons
rsv
f
nanoparticl
vaccin
cotton
rat
n
immun
day
firsv
rsvf
nanoparticl
vaccin
without
adjupho
addit
group
receiv
palivizumab
mgkg
intramuscularli
day
one
day
prior
challeng
placebo
group
serv
neg
control
sera
obtain
group
day
prior
challeng
panel
rsv
f
igg
respons
determin
elisa
express
gmt
ci
panel
b
palivizumab
compet
antibodi
pca
report
gml
antibodi
requir
inhibit
bind
palivizumab
rsv
f
panel
c
neutral
antibodi
titer
provid
inhibit
cpe
gmt
group
shown
ci
p
valu
ns
signific
compar
rsvinfect
group
twotail
student
ttest
lod
lower
limit
detect
gmt
compar
challeng
cotton
rat
pfug
tissu
gmt
fail
confer
full
protect
viral
replic
evalu
nasal
compart
rsv
f
vaccin
adjuv
rsv
infect
group
complet
protect
fig
cotton
rat
receiv
unadjuv
rsv
f
palivizumab
reduc
viral
load
compar
anim
group
readili
measur
viru
titer
nasal
tissu
follow
challeng
fig
lot
firsv
vaccin
use
clinic
trial
late
vaccin
children
develop
enhanc
respiratori
diseas
erd
upon
reinfect
similarli
erd
reproduc
cotton
rat
model
vaccin
known
lot
firsv
vaccin
current
studi
lot
firsv
induc
promin
alveol
perivascul
lung
rsv
challeng
anim
consist
erd
convers
signific
lung
histopatholog
chang
magnitud
observ
cotton
rat
immun
rsv
f
nanoparticl
vaccin
administ
without
adjuv
similar
minim
chang
seen
placebo
palivizumab
anim
fig
rsv
f
vaccin
deriv
rsv
long
sequenc
dose
rang
immun
rsv
f
vaccin
undertaken
compar
protect
efficaci
vaccin
nonhomolog
challeng
rsv
b
palivizumab
known
protect
rsv
b
cotton
rat
immun
g
dose
adjuv
rsv
f
vaccin
day
palivizumab
given
dose
mgkg
one
day
prior
challeng
rsv
f
nanoparticl
vaccin
palivizumab
induc
serum
antirsv
f
igg
titer
high
dose
depend
gmt
gmt
respect
fig
similarli
level
pca
robust
group
receiv
adjuv
rsv
f
vaccin
pca
titer
anim
passiv
transfer
palivizumab
significantli
lower
observ
mgkg
dose
gml
cotton
rat
receiv
mgkg
palivizumab
pca
titer
level
detect
gml
fig
neutral
antibodi
rsva
rsvb
induc
dosedepend
manner
fig
even
lowest
dose
g
rsv
f
vaccin
induc
signific
level
neutral
antibodi
rsva
long
rsvb
neutral
titer
mgkg
palivizumab
group
compar
induc
anim
activ
immun
lowest
dose
g
rsv
f
vaccin
fig
vivo
protect
efficaci
rsv
f
nanoparticl
vaccin
evalu
direct
comparison
palivizumab
measur
inhibit
viral
replic
lung
nasal
passag
cotton
rat
challeng
rsvb
postchalleng
lung
viru
titer
gmt
lod
anim
given
lowest
dose
rsv
f
g
lod
recipi
higher
dose
rsv
f
vaccin
fig
rsv
lung
viru
titer
log
placebo
group
fig
palivizumab
also
reduc
lung
rsv
titer
lod
detect
viru
lowest
dose
consist
previous
observ
reduct
rsv
titer
nasal
passag
also
observ
dose
depend
manner
rsv
f
vaccin
palivizumab
rel
lower
viru
level
rsv
f
vaccin
group
concert
level
neutral
titer
induc
fig
thu
rsv
f
vaccin
protect
nonhomolog
viru
challeng
upper
lower
respiratori
tract
appear
potent
immunogen
provid
protect
via
activ
immun
exceed
seen
palivizumab
despit
use
low
dose
vaccin
passiv
immunizationviru
challeng
studi
done
compar
rel
potenc
vaccin
measur
pca
assay
rel
palivizumab
cotton
rat
receiv
im
inject
pool
cotton
rat
antirsv
f
serum
deliv
pca
dose
mgkg
similar
rang
palivizumab
mgkg
one
day
prior
rsv
challeng
h
administr
antirsv
f
antibodi
level
rsv
f
igg
antibodi
high
dose
depend
group
except
group
receiv
normal
cotton
rat
serum
fig
titer
similar
highest
dose
palivizumab
immun
antisera
administ
gmt
respect
one
day
follow
passiv
immun
day
pca
level
significantli
higher
group
receiv
rsv
f
antisera
p
given
similar
dose
palivizumab
measur
pca
assay
fig
palivizumab
treat
anim
pca
serum
titer
lod
assay
except
highest
dose
wherea
pca
serum
level
cotton
rat
passiv
immun
antirsv
f
serum
gml
gml
mgkg
dose
level
respect
group
challeng
hour
passiv
immun
day
pfu
rsva
long
viru
lung
tissu
collect
day
post
challeng
determin
viral
titer
plaqu
assay
homogen
tissu
highest
dose
antirsv
f
immun
sera
mgkg
palivizumab
mgkg
confer
appar
gmt
group
shown
bar
p
compar
g
rsv
f
group
p
compar
g
rsv
f
group
lod
lower
limit
detect
limit
detect
assay
complet
protect
fig
reduc
viru
replic
lung
rel
placebo
viru
replic
also
significantli
reduc
anim
given
mgkg
antirsv
f
immun
sera
compar
group
receiv
preimmun
sera
p
fig
palivizumab
mgkg
induc
slight
reduct
lung
viru
titer
statist
signific
compar
group
receiv
preimmun
sera
fig
beeler
et
al
identifi
multipl
neutral
epitop
rsv
f
protein
use
competit
bind
assay
panel
rsv
f
monoclon
antibodi
monoclon
antibodi
resist
mutant
marm
subsequ
antigen
site
ii
iv
v
iv
map
rsv
f
competit
elisa
perform
use
monoclon
antibodi
identifi
neutral
antibodi
induc
rsv
f
vaccin
antibodi
map
antigen
site
ii
broadli
reactiv
site
iv
v
vi
tabl
polyclon
cotton
rat
sera
rais
rsv
f
nanoparticl
vaccin
competit
rsv
f
monoclon
antibodi
tabl
antibodi
competit
antigen
site
ii
monoclon
antibodi
induc
vaccin
without
adjuv
respect
minim
site
ii
competit
antibodi
detect
sera
firsv
immun
rsv
infect
anim
tabl
rsv
f
vaccin
also
induc
polyclon
respons
competit
neutral
antibodi
rsva
long
rsv
f
rsv
f
adjupho
denot
lower
limit
detect
lod
competit
elisa
mab
compet
antibodi
mca
report
polyclon
anti
rsv
f
antibodi
titer
requir
inhibit
bind
mab
rsv
f
recogn
rsv
f
antigen
site
iv
v
vi
tabl
rsvrelat
lower
respiratori
tract
diseas
common
caus
hospit
infant
common
basi
infant
pediatr
medic
visit
signific
pathogen
elderli
highrisk
adult
sever
rsv
infect
young
children
clearli
associ
ongo
repeat
episod
wheez
popul
describ
may
benefit
vaccin
rsv
fvaccin
popul
requir
uniqu
vaccin
strategi
clinic
develop
program
passiv
antibodi
prophylaxi
shown
effect
reduc
seriou
rsv
diseas
human
induct
immun
respons
antigen
site
ii
strongli
consid
develop
rsv
vaccin
show
rsv
f
nanoparticl
vaccin
induc
immun
respons
target
site
ii
f
protein
associ
function
protect
immun
cotton
rat
serial
develop
rsv
prophylact
product
respigam
palivizumab
motavizumab
first
evalu
cotton
rat
model
reliabl
predict
clinic
outcom
base
preclin
data
passiv
prophylaxi
studi
advanc
use
palivizumab
motavizumab
shown
reduc
rsvrelat
hospit
preterm
high
risk
term
infant
recent
clinic
studi
found
vaccin
elicit
antibodi
rsv
f
nanoparticl
vaccin
avidli
bind
site
ii
epitop
clearli
import
observ
associ
vaccineinduc
immun
respons
novel
vaccin
data
show
prevent
rsv
diseas
five
random
clinic
trial
current
studi
use
array
antibodi
assay
character
explor
implic
product
vaccineinduc
pca
cotton
rat
model
studi
use
import
control
palivizumab
assess
rel
potenc
vaccin
activ
passiv
assess
recent
avail
lot
formalin
inactiv
vaccin
histor
associ
clinic
diseas
enhanc
allow
compar
evalu
safeti
function
immun
measur
pca
neutral
assay
protect
clinic
relev
model
vaccin
shown
safe
potent
elicit
high
level
neutral
pca
antif
antibodi
protect
homolog
nonhomolog
strain
viral
challeng
protect
seen
activ
immun
could
reproduc
use
passiv
inject
immun
sera
appear
dose
dose
potent
potent
palivizumab
final
rsv
f
vaccin
also
found
elicit
antibodi
known
bind
nonpalivizumab
f
protein
bind
site
associ
neutral
without
evid
diseas
enhanc
observ
neither
adult
human
decad
rsv
infect
cotton
rat
live
viru
challeng
elicit
pca
robust
manner
great
interest
warrant
studi
absenc
pca
infect
absolut
question
whether
presenc
natur
antibodi
confer
protect
focu
futur
studi
fusion
activ
critic
viral
pathogenesi
antibodi
bind
site
ii
disrupt
fusion
activ
togeth
suggest
select
pressur
favor
immunolog
cryptic
site
ii
univers
natur
vaccin
protect
homolog
nonhomolog
viru
absenc
robust
natur
immun
antigen
critic
pathogenesi
site
ii
f
protein
genet
stabil
palivizumab
bind
site
compar
site
antigen
site
safeti
appar
potenc
vaccin
reinforc
premis
efficaci
test
vaccin
warrant
clinic
develop
rsv
vaccin
may
divid
amongst
three
popul
infant
infantspreschool
children
elderli
matern
immun
activ
immun
pregnant
women
provid
transplacent
transfer
antibodi
passiv
protect
infant
prioriti
strategi
protect
young
infant
rsv
success
employ
tetanu
pertussi
influenza
vaccin
older
infant
toddler
may
also
benefit
activ
immun
mani
strategi
includ
live
viral
vaccin
purifi
subunit
vaccin
employ
earli
clinic
test
rsv
purifi
f
protein
show
clinic
promis
children
cf
patient
prove
difficult
manufactur
stabil
clinic
evalu
novel
vaccin
must
also
take
account
histori
formalin
inactiv
rsv
vaccin
pfizer
lot
vaccin
unexpectedli
caus
sever
exacerb
pulmonari
diseas
children
subsequ
acquir
rsv
infect
although
precis
mechan
underli
find
remain
open
debat
phenomenon
vaccineenhanc
rsv
diseas
limit
infant
immun
firsv
observ
either
passiv
antibodi
prophylaxi
monoclon
polyclon
clinic
trial
use
purifi
f
protein
vaccin
adult
older
rsvseroposit
children
thu
path
forward
develop
vaccin
older
infant
children
need
care
consid
howev
vaccin
induc
high
affin
antibodi
exhibit
neutral
fusion
inhibit
vitro
larg
absent
firsv
vaccin
infant
associ
protect
without
diseas
exacerb
vivo
relev
anim
model
final
show
efficaci
anoth
set
matern
immun
may
consid
absenc
licens
vaccin
popul
final
rsv
diseas
burden
elderli
high
risk
adult
data
indic
f
subunit
vaccin
safe
along
absenc
histor
safeti
concern
due
enhanc
diseas
popul
suggest
test
safeti
efficaci
season
respiratori
vaccin
warrant
induct
pca
rsv
f
nanoparticl
vaccin
provid
import
rational
clinic
evalu
relev
suscept
popul
